Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 16.7%

Replimune Group, Inc. (NASDAQ:REPL) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 8,470,000 shares, an increase of 16.7% from the January 15th total of 7,260,000 shares. Based on an average trading volume of 885,200 shares, the short-interest ratio is currently 9.6 days.

Insider Activity

In related news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the business. Sterling Capital Management LLC raised its stake in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd grew its holdings in Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after purchasing an additional 8,183 shares during the period. XTX Topco Ltd acquired a new position in Replimune Group during the fourth quarter valued at approximately $137,000. Finally, Freestone Grove Partners LP acquired a new position in Replimune Group during the fourth quarter valued at approximately $140,000. 92.53% of the stock is owned by institutional investors.

Replimune Group Price Performance

Shares of REPL traded down $0.19 on Friday, reaching $14.10. 431,744 shares of the company’s stock were exchanged, compared to its average volume of 790,791. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The business has a 50 day moving average price of $12.54 and a two-hundred day moving average price of $11.73. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Research analysts expect that Replimune Group will post -2.88 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $19.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.